Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Paychex, Inc. (PAYX) Price & Performance

Heron Therapeutics IncTrade
Paychex, Inc.Trade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Paychex, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Paychex, Inc. trades at $121.14 (market cap $43.10B). The key difference: Paychex, Inc. is far larger — about 679.7× Heron Therapeutics Inc's market cap, and Paychex, Inc. pays a 3.93% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXPAYX
Market Cap
$63.41M$43.10B
Sector
HealthIndustrials
52-Week High
$1.49$140.81
52-Week Low
$0.32$85.57
Enterprise Value
$161.31M$46.59B
Dividend Yield
3.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Paychex, Inc.

Paychex (PAYX) trades at $120.04, down slightly by 0.07% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.32 exceeding the $1.31 estimate. Revenue grew to $5.57 billion in 2025, though net income margin dipped to 27.03%. Recent news highlights expansion of its WISE platform and steady small business employment trends, supporting growth prospects.

The outlook remains positive given consistent earnings outperformance and strategic initiatives, but risks include elevated valuation ratios and potential economic sensitivity. Analyst consensus is mixed with a hold-heavy rating, and the current price sits above the $114.50 target, suggesting limited near-term upside. Dividend payments provide income support, yet investors should weigh growth against premium multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Paychex, Inc.

Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.

Read more on PAYX